189 related articles for article (PubMed ID: 24109191)
1. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model.
Ackerman S; D'Ambrosio F; Greiner JV; Villanueva L; Ciolino JB; Hollander DA
J Asthma Allergy; 2013; 6():43-52. PubMed ID: 24109191
[TBL] [Abstract][Full Text] [Related]
2. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials.
McLaurin EB; Marsico NP; Ackerman SL; Ciolino JB; Williams JM; Villanueva L; Hollander DA
Adv Ther; 2014 Oct; 31(10):1059-71. PubMed ID: 25260889
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%.
Greiner JV; Edwards-Swanson K; Ingerman A
Clin Ophthalmol; 2011 Jan; 5():87-93. PubMed ID: 21339800
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Spangler DL; Abelson MB; Ober A; Gotnes PJ
Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
Butrus S; Greiner JV; Discepola M; Finegold I
Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
Torkildsen GL; Abelson MB; Gomes PJ
Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.
Torkildsen G; Narvekar A; Bergmann M
Clin Ophthalmol; 2015; 9():1703-13. PubMed ID: 26392751
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
Abelson MB; Turner D
Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
[TBL] [Abstract][Full Text] [Related]
14. Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials.
Ciolino JB; McLaurin EB; Marsico NP; Ackerman SL; Williams JM; Villanueva L; Hollander DA
Clin Ophthalmol; 2015; 9():765-72. PubMed ID: 25999684
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
Deschenes J; Discepola M; Abelson M
Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
[TBL] [Abstract][Full Text] [Related]
20. Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study.
Nakatani H; Gomes P; Bradford R; Guo Q; Safyan E; Hollander DA
Ocul Immunol Inflamm; 2019; 27(4):622-631. PubMed ID: 29543548
[No Abstract] [Full Text] [Related]
[Next] [New Search]
